Advanced Biomed Executes 1-for-20 Reverse Split, Reduces Shares to 1.36M
Advanced Biomed will implement a 1-for-20 reverse stock split on February 20, 2026, reducing its issued shares from 27,290,710 to approximately 1,364,536 to satisfy Nasdaq’s $1.00 minimum bid requirement. The consolidation will not alter ownership percentages and eliminates fractional share issuance.
1. Reverse Split Implementation
On February 20, 2026, Advanced Biomed will combine every 20 issued common shares into one share, reducing its outstanding count from 27,290,710 to approximately 1,364,536 under a new CUSIP number.
2. Nasdaq Compliance Objective
The board approved the 1-for-20 ratio to satisfy Nasdaq Capital Market Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per share for continued listing.
3. Shareholder Impact
All stockholders will see uniform share adjustments with no fractional shares issued; brokerage account holders need not take any action and ownership percentages remain largely unchanged.
4. Company Background
Advanced Biomed is a biotechnology firm focused on microfluidic platforms for circulating tumor cell detection and analysis, with regulatory clearances under review in Taiwan and plans for global market expansion.